0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Release of Thyrotropin and Prolactin by a Thyrotropin-Releasing Hormone (TRH) Precursor, TRH-Gly: Conversion to TRH Is Sufficient for in vivo Effects

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The mechanism by which TRH-Gly (pGlu-His-Pro-Gly), a biosynthetic precursor of thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH<sub>2</sub>), stimulates pituitary thyrotropin (TSH) and prolactin release has been studied in urethane-anesthetized 2-month-old (250 g) male Sprague-Dawley rats and in vitro with GH<Sub>3</Sub> cells, a rat anterior pituitary tumor cell line. We used specific radioimmunoassays to measure TRH-Gly and TRH levels in rat cortex, hypothalamus, medulla, eyes and whole blood as a function of the intracisternal (IC) dose of TRH and TRH-Gly administered 40 min prior to sacrifice. IC injection of 1.0 mg of TRH-Gly led to a significant (p < 0.005) increase in the TRH levels in hypothalamus, medulla and blood. The relative potency of IC and intracardiac (IK) TRH and TRH-Gly release of rat TSH was compared by radioimmunoassay and further refined using estimates based on in vivo kinetics of TRH-Gly alpha-amidation. The binding of TRH-Gly to the plasma membrane receptors for TRH on GH<sub>3</sub> cells was also investigated. In regard to TSH release, TRH-Gly given IC had only 0.042% of the potency of TRH given IC and was consistent with its rate of IC alpha-amidation. IK TRH-Gly had 0.16% of the potency of IK TRH of TSH release and was also consistent with its rate of intravascular conversion to TRH. The mean peak TSH response occurred at 20 min after IC TRH-Gly or IC TRH injection but the post-peak decline was slower for IC TRH-Gly. The maximum levels of blood TRH-Gly and TRH both occurred at 20 min after IC administration of TRH-Gly and TRH, respectively. The agreement between the directly measured relative potency for TSH release following IC TRH-Gly and that derived from the rate of IC TRH-Gly conversion to TRH suggests that IC TRH-Gly must first be converted to TRH by alpha-amidating enzymes in the cerebrospinal fluid before it transits the blood-brain barrier. TRH-Gly cross-reactivity with the TRH receptor of GH<sub>3</sub> cells was 0.45% of that for TRH while the in vitro potency of prolactin release by GH<sub>3</sub> cells in response to TRH-Gly was 0.41% that for TRH. GH<sub>3</sub> cells incubated for 3 h with or without 50 µg TRH-Gly/ml revealed no significant increase in extracellular or intracellular TRH concentration. We conclude that conversion of TRH-Gly to TRH is the most likely explanation for the stimulation of TSH release in rats but in vitro release of prolactin from GH<sub>3</sub> cells in response to TRH-Gly administration may be mediated via TRH-Gly cross-reaction with the TRH receptor.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1990
          1990
          03 April 2008
          : 52
          : 6
          : 618-625
          Affiliations
          aEndocrinology and bGastroenterology Research Laboratories, VA Wadsworth Medical Center and cUCLA Biocybernetics Laboratory, and dDepartment of Medicine, Los Angeles, Calif., USA
          Article
          125654 Neuroendocrinology 1990;52:618–625
          10.1159/000125654
          2126612
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article